Clinical Trials in the National Cancer Institute's Database
ACUTE LYMPHOBLASTIC LEUKEMIA
Combination Chemotherapy with or without Blinatumomab in Treating Patients with Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia
Status: Active
Phase III
Age: 30 to 70 years
Gender: Male or Female
Location: 412 locations
Primary ID E1910
Secondary IDs NCI-2013-02229, ECOG-E1910, PE1910_A08PAMDREVW01
Clinicaltrials.gov ID NCT02003222
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults with Newly Diagnosed B Acute Lymphoblastic Leukemia
Status: Active
Phase III
Age: 18 to 39 years
Gender: Male or Female
Location: 201 locations
Primary ID A041501
Secondary IDs NCI-2016-01981
Clinicaltrials.gov ID NCT03150693
Combination Chemotherapy in Treating Young Patients with Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations
Status: Active
Phase III
Age: 1 to 30 years
Gender: Male or Female
Location: 192 locations
Primary ID AALL1131
Secondary IDs NCI-2011-03797, CDR0000706370, NCT01406756, COG-AALL1131, S12-01254
Clinicaltrials.gov ID NCT02883049
Blinatumomab in Treating Younger Patients with Relapsed B-cell Acute Lymphoblastic Leukemia
Status: Active
Phase III
Age: 1 to 30 years
Gender: Male or Female
Location: 162 locations
Primary ID AALL1331
Secondary IDs NCI-2014-00631, COG-AALL1331, s15-00970
Clinicaltrials.gov ID NCT02101853
Imatinib Mesylate and Combination Chemotherapy in Treating Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Status: Active
Phase III
Age: 2 to 21 years
Gender: Male or Female
Location: 137 locations
Primary ID AALL1631
Secondary IDs NCI-2016-01588
Clinicaltrials.gov ID NCT03007147
Inotuzumab Ozogamicin in Treating Younger Patients with B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
Status: Active
Phase II
Age: 1 to 21 years
Gender: Male or Female
Location: 127 locations
Primary ID AALL1621
Secondary IDs NCI-2016-01494
Clinicaltrials.gov ID NCT02981628
Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients with Acute Lymphoblastic Leukemia
Status: Active
Phase II
Age: 65 years and over
Gender: Male or Female
Location: 156 locations
Primary ID S1318
Secondary IDs NCI-2014-01047, SWOG-S1318
Clinicaltrials.gov ID NCT02143414
A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
Status: Active
Phase II
Age: 1 to 21 years
Gender: Male or Female
Location: 30 locations
Primary ID INCB 18424-269
Secondary IDs NCI-2016-01687, AALL1521
Clinicaltrials.gov ID NCT02723994
Bortezomib, Vorinostat, and Combination Chemotherapy in Treating Infants with Newly Diagnosed Acute Lymphoblastic Leukemia
Status: Active
Phase I/II
Age: 1 year and under
Gender: Male or Female
Location: 11 locations
Primary ID TINI
Secondary IDs NCI-2015-01493
Clinicaltrials.gov ID NCT02553460
A Study Evaluating KTE-X19 in Adult Subjects With Relapsed / Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-3)
Status: Active
Phase I/II
Age: 18 years and over
Gender: Male or Female
Location: 17 locations
Primary ID KTE-C19-103
Secondary IDs NCI-2015-02272, 2015-005009-35
Clinicaltrials.gov ID NCT02614066
BLADDER CANCER
Pembrolizumab in Treating Patients with Locally Advanced Bladder Cancer
Status: Active
Phase III
Age: 18 years and over
Gender: Male or Female
Location: 644 locations
Primary ID A031501
Secondary IDs NCI-2017-01425
Clinicaltrials.gov ID NCT03244384
Gemcitabine Hydrochloride and Cisplatin in Treating Participants with Invasive Bladder Urothelial Cancer
Status: Active
Phase II
Age: 18 years and over
Gender: Male or Female
Location: 290 locations
Primary ID A031701
Secondary IDs NCI-2018-01531
Clinicaltrials.gov ID NCT03609216
Atezolizumab in Treating Patients with Recurrent BCG-Unresponsive Non-muscle Invasive Bladder Cancer
Status: Active
Phase II
Age: 18 years and over
Gender: Male or Female
Location: 248 locations
Primary ID S1605
Secondary IDs NCI-2016-01104
Clinicaltrials.gov ID NCT02844816
Different Versions of BCG with or without Vaccine Therapy in Treating Patients with High Grade Bladder Cancer That Is Not Muscle Invasive
Status: Active
Phase III
Age: Not specified
Gender: Male or Female
Location: 110 locations
Primary ID S1602
Secondary IDs NCI-2016-00451
Clinicaltrials.gov ID NCT03091660
Cisplatin and Gemcitabine Hydrochloride with or without ATR Kinase Inhibitor M6620 in Treating Patients with Metastatic Urothelial Cancer
Status: Active
Phase II
Age: 18 years and over
Gender: Male or Female
Location: 35 locations
Primary ID 9947
Secondary IDs NCI-2015-01642, PHII-135
Clinicaltrials.gov ID NCT02567409
A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Status: Active
Phase II
Age: 18 years and over
Gender: Male or Female
Location: 24 locations
Primary ID SGN22E-001
Secondary IDs NCI-2017-01866
Clinicaltrials.gov ID NCT03219333
Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Status: Active
Phase I
Age: 18 years and over
Gender: Male or Female
Location: 24 locations
Primary ID CPI-444-001
Secondary IDs NCI-2016-00227
Clinicaltrials.gov ID NCT02655822
Neratinib HER Mutation Basket Study (SUMMIT)
Status: Active
Phase II
Age: 18 years and over
Gender: Male or Female
Location: 22 locations
Primary ID PUMA-NER-5201
Secondary IDs NCI-2014-00495, 2013-002872-42
Clinicaltrials.gov ID NCT01953926
CERVICAL CANCER
Radiation Therapy with or without Chemotherapy in Patients with Stage I-IIA Cervical Cancer Who Previously Underwent Surgery
Status: Active
Phase III
Age: 18 years and over
Gender: Female
Location: 378 locations
Primary ID GOG-0263
Secondary IDs NCI-2011-02037, CDR0000670125
Clinicaltrials.gov ID NCT01101451
Chemotherapy and Pelvic Radiation Therapy with or without Additional Chemotherapy in Treating Patients with High-Risk Early-Stage Cervical Cancer after Radical Hysterectomy
Status: Active
Phase III
Age: 18 years and over
Gender: Female
Location: 151 locations
Primary ID RTOG 0724/GOG-0724
Secondary IDs RTOG-0724, NCI-2011-01973, CDR0000654709, GOG-0724
Clinicaltrials.gov ID NCT00980954
Radiation Therapy and Cisplatin with or without Triapine in Treating Patients with Newly Diagnosed Stage IB2, II, or IIIB-IVA Cervical Cancer or Stage II-IVA Vaginal Cancer
Status: Active
Phase II
Age: 18 years and over
Gender: Female
Location: 254 locations
Primary ID NRG-GY006
Secondary IDs NCI-2015-00835
Clinicaltrials.gov ID NCT02466971
An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors
Status: Active
Phase I/II
Age: 12 years and over
Gender: Male or Female
Location: 15 locations
Primary ID CA224-020
Secondary IDs NCI-2014-00315, 2014-002605-38
Clinicaltrials.gov ID NCT01968109
Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas
Status: Active
Phase I/II
Age: 18 years and over
Gender: Male or Female
Location: 13 locations
Primary ID ASTX660-01
Secondary IDs NCI-2017-01760
Clinicaltrials.gov ID NCT02503423
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158 / KEYNOTE-158)
Status: Active
Phase II
Age: 18 years and over
Gender: Male or Female
Location: 11 locations
Primary ID 3475-158
Secondary IDs NCI-2015-02278, 163196, 2015-002067-41
Clinicaltrials.gov ID NCT02628067
Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer
Status: Active
Phase III
Age: 18 years and over
Gender: Female
Location: 13 locations
Primary ID ADXS001-02
Secondary IDs NCI-2017-00295
Clinicaltrials.gov ID NCT02853604
Intensity Modulated Radiation Therapy in Treating Patients with Cervical Cancers
Status: Active
Phase II/III
Age: 18 years and over
Gender: Female
Location: 2 locations
Primary ID 110808
Secondary IDs NCI-2012-02858
Clinicaltrials.gov ID NCT01554397
ESOPHAGEAL CANCER
An Investigational Immuno-therapy Study of Nivolumab or Placebo in Patients With Resected Esophageal or Gastroesophageal Junction Cancer
Status: Active
Phase III
Age: 18 years and over
Gender: Male or Female
Location: 20 locations
Primary ID CA209-577
Secondary IDs NCI-2016-00858, 2015-005556-10, s16-00474
Clinicaltrials.gov ID NCT02743494
First-line Esophageal Carcinoma Study With Chemo vs. Chemo Plus Pembrolizumab (MK-3475-590 / KEYNOTE-590)
Status: Active
Phase III
Age: 18 years and over
Gender: Male or Female
Location: 12 locations
Primary ID 3475-590
Secondary IDs NCI-2017-02500, 173739, 2017-000958-19
Clinicaltrials.gov ID NCT03189719
A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab
Status: Active
Phase I
Age: 18 years and over
Gender: Male or Female
Location: 8 locations
Primary ID DEK-DKK1-P102
Secondary IDs NCI-2014-00704, DKN-01, LY2812176
Clinicaltrials.gov ID NCT02013154
Afatinib Dimaleate and Paclitaxel in Treating Patients with Trastuzumab-Refractory Metastatic Esophagus or Stomach Cancer
Status: Active
Phase II
Age: 18 years and over
Gender: Male or Female
Location: 10 locations
Primary ID 11-166
Secondary IDs NCI-2012-00414
Clinicaltrials.gov ID NCT01522768
Pembrolizumab, Trastuzumab, Fluorouracil, and Combination Chemotherapy as First Line Therapy in Treating Patients with HER2-Positive Stage IV Esophagogastric Cancer
Status: Active
Phase II
Age: 18 years and over
Gender: Male or Female
Location: 8 locations
Primary ID 16-937
Secondary IDs NCI-2016-01716
Clinicaltrials.gov ID NCT02954536
Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer
Status: Active
Phase I/II
Age: 18 years and over
Gender: Male or Female
Location: 8 locations
Primary ID CP-MGAH22-05
Secondary IDs NCI-2016-00290
Clinicaltrials.gov ID NCT02689284
A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands
Status: Active
Phase I
Age: 18 years and over
Gender: Male or Female
Location: 7 locations
Primary ID CLGK974X2101
Secondary IDs NCI-2011-03693, 2011-000495-33
Clinicaltrials.gov ID NCT01351103
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Status: Active
Phase I/II
Age: 18 years and over
Gender: Male or Female
Location: 8 locations
Primary ID INCAGN 1876-201
Secondary IDs NCI-2017-01296
Clinicaltrials.gov ID NCT03126110
A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin
Status: Active
Phase III
Age: 18 years and over
Gender: Male or Female
Location: 5 locations
Primary ID CA209-648
Secondary IDs NCI-2017-00937, 2016-001514-20
Clinicaltrials.gov ID NCT03143153
Durvalumab, Chemotherapy, and Radiation Therapy before Surgery in Treating Patients with Esophageal or Gastroesophageal Junction Cancer
Status: Active
Phase II
Age: 18 years and over
Gender: Male or Female
Location: 5 locations
Primary ID 16-1405
Secondary IDs NCI-2016-01758
Clinicaltrials.gov ID NCT02962063
GLIOBLASTOMA
Veliparib, Radiation Therapy, and Temozolomide in Treating Participants with Newly Diagnosed Malignant Glioma without H3 K27M or BRAFV600E Mutations
Status: Active
Phase II
Age: 3 to 25 years
Gender: Male or Female
Location: 74 locations
Primary ID ACNS1721
Secondary IDs NCI-2018-01361
Clinicaltrials.gov ID NCT03581292
Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients with Newly Diagnosed Glioblastoma
Status: Active
Phase II
Age: 18 years and over
Gender: Male or Female
Location: 159 locations
Primary ID NRG-BN001
Secondary IDs NCI-2014-01072
Clinicaltrials.gov ID NCT02179086
Selinexor in Treating Younger Patients with Recurrent or Refractory Solid Tumors or High-Grade Gliomas
Status: Active
Phase I
Age: 1 to 21 years
Gender: Male or Female
Location: 22 locations
Primary ID ADVL1414
Secondary IDs NCI-2014-02410
Clinicaltrials.gov ID NCT02323880
A Study of TAS-120 in Patients With Advanced Solid Tumors
Status: Active
Phase I/II
Age: 18 years and over
Gender: Male or Female
Location: 20 locations
Primary ID TPU-TAS-120-101
Secondary IDs NCI-2014-01148, 2013-004810-16
Clinicaltrials.gov ID NCT02052778